11:44 AM EST - Valeant Pharmaceuticals International, Inc. : announced financial results for 2013. Total revenue was $5.8 billion; an increase of 66% over the prior year. The company endured a loss for the year, however, of $863 million, compared to a loss of $116 million in fiscal 2012. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $3.45 at $165.83.
